Ann: June Quarterly Activities Report, page-13

The ugly:

So basically the accounting book value of the company is 0 or negative now.

C2V (owned by Directors Niall Cairns and Craig Cooper) gave a lifeline debt to the company at 10% interest upgradeable to 15% and convertible to stock. (search for FUNDING COMMITMENT AGREEMENT)

Revenue this FY will be very high but due to H1'24 in which we had a big revenue for the historical atcor division on some heart studies they were supposed to do but didn't (but we got paid regardless).

Company spend money trying to go for watch wearables (no uptake).
Company spend money trying to list on Nasdaq with no results


The good:

Inside ownership of 35%
Sales of atcor tech to conteqt pulse potentially creating a new market

Neutral:

Company previous name AtCor Medical Holdings Limited, change listing to CDX 1 June 2018
Previous management focused on less growth/flashy things and more steady but small revenues through studies and developing the atcor tech